Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
Prometheus Biosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference
March 09, 2023 08:30 ET
|
Prometheus Biosciences
SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...
Prometheus Biosciences Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Progress
February 28, 2023 16:00 ET
|
Prometheus Biosciences
– Reported strong efficacy and favorable safety results for PRA023 in ARTEMIS-UC and APOLLO-CD Phase 2 Studies – – Prometheus intends to advance PRA023 into Phase 3 studies for UC and CD in 2023 – ...
Prometheus Biosciences Announces Two Oral Presentations on PRA023 at the 18th Congress of European Crohn’s and Colitis Organisation (ECCO)
February 22, 2023 16:00 ET
|
Prometheus Biosciences
- Digital Oral Presentation on APOLLO-CD Phase 2a primary and secondary results to be presented on March 3rd - - Oral Presentation on ARTEMIS-UC Phase 2 primary and secondary endpoint data from...
Prometheus Biosciences to Present at the SVB Securities Global Biopharma Conference
February 09, 2023 16:00 ET
|
Prometheus Biosciences
SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...
Prometheus Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 08:30 ET
|
Prometheus Biosciences
SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...
Prometheus Biosciences, Inc. Announces Pricing of Public Upsized $500 Million Offering of Common Stock
December 08, 2022 19:39 ET
|
Prometheus Biosciences
SAN DIEGO, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...
Prometheus Biosciences, Inc. Announces Proposed Public Offering of Common Stock
December 07, 2022 16:01 ET
|
Prometheus Biosciences
SAN DIEGO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...
Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb
December 07, 2022 07:00 ET
|
Prometheus Biosciences
– ARTEMIS-UC trial met primary endpoint with 26.5% of patients on PRA023 achieving clinical remission compared to 1.5% of patients on placebo at Week 12 (p<0.0001) – – ARTEMIS-UC Cohort 1 met all...
Prometheus Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress
November 09, 2022 16:01 ET
|
Prometheus Biosciences
- On track for topline ARTEMIS-UC Phase 2 and full APOLLO-CD Phase 2a results concurrently in 4Q 2022 - - Initiation of Phase 1 trial of second precision program PRA052 - - Strong cash position...
Prometheus Biosciences to Participate at November Healthcare Conferences
November 01, 2022 08:00 ET
|
Prometheus Biosciences
SAN DIEGO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...